Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Are you dealing with multiple myeloma that keeps coming back or hasn't improved? If you are, you may be able to join a study to see if a new drug called ABBV-383 could be safe and helpful for people in your situation. You will be reimbursed for travel expenses. You will not have to pay for the drug while you take part in this study.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Do you have multiple myeloma with MGRS-associated kidney disease? If so, you may be able to take part in a research study looking at the safety and effectiveness of a combination of medications for patients with multiple myeloma with MGRS-associated kidney disease.

The purpose of this study is to understand what factors encourage and discourage rural and racially and ethnically diverse populations to participate in cancer clinical research studies. The study is focused on people living in Bertie, Hertford, Robseon and Scotland Co, NC and neighboring counties. We also want to hear what healthcare providers in these NC areas think about cancer clinical research barriers and facilitators.

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).